2-phenylindole and arylsulphonamide: Novel scaffolds bactericidal against mycobacterium tuberculosis

ACS Medicinal Chemistry Letters

Volumn 5, Issue 9, 2014, Pages 1005-1009

  Naik, Maruti ^a   Ghorpade, Sandeep ^a   Jena, Lalit Kumar ^a   Gorai, Gopinath ^a   Narayan, Ashwini ^a   Guptha, Supreeth ^a   Sharma, Sreevalli ^a   Dinesh, Neela ^a   Kaur, Parvinder ^a   Nandishaiah, Radha ^a   Bhat, Jyothi ^a   Balakrishnan, Gayathri ^a   Humnabadkar, Vaishali ^a   Ramachandran, Vasanthi ^a   Naviri, Lava Kumar ^a   Khadtare, Pallavi ^a   Panda, Manoranjan ^a   Iyer, Pravin S ^a   Chatterji, Monalisa ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

2 phenylindoles; arylsulphonamides; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

2 PHENYLINDOLE DERIVATIVE; ADENINE; ANTIINFECTIVE AGENT; ARYLSULPHONAMIDE DERIVATIVE; BEDAQUILINE; CAMPTOTHECIN; CHLORAMPHENICOL; DNA TOPOISOMERASE; ETHAMBUTOL; ISONIAZID; LEUCINE; NOVOBIOCIN; RIFAMPICIN; RNA POLYMERASE; SPARFLOXACIN; SULFONAMIDE; UNCLASSIFIED DRUG; URACIL;

ARTICLE; BACTERICIDAL ACTIVITY; BROMINATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IC50; IN VITRO STUDY; INTRACELLULAR BACTERIUM; KLEBSIELLA PNEUMONIAE; MACROPHAGE; MAMMAL CELL; MANNICH REACTION; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHYSICAL CHEMISTRY; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; RACEMIC MIXTURE; STAPHYLOCOCCUS AUREUS; STEREOCHEMISTRY; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

EID: 84907555819     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5001933     Document Type: Article

References (14)

1. World Health Organization. Global Tuberculosis Report 2012.
2. Meeting Report "Totally Drug-Resistant TB": a WHO consultation on the diagnostic definition and treatment options; WHO/HQ: Geneva, Switzerland, 2012.
3. Jones, D. Tuberculosis success Nat. Rev. Drug Discovery 2013, 12, 175-176
4. Smith, I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence Clin. Microbiol. Rev. 2003, 16, 463-496
5. Zumla, A.; Nahid, P.; Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens Nat. Rev. Drug Discovery 2013, 12, 388-404
6. Almeida Da Silva, P. E.; Palomino, J. C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs J. Antimicrob. Chemother. 2011, 66, 1417-1430
7. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 2007, 3, 323-324
8. Tahlan, K.; Wilson, R.; Kastrinsky, D. B.; Arora, K.; Nair, V.; Fischer, E.; Barnes, S. W.; Walker, J. R.; Alland, D.; Barry, C. E., III; Boshoff, H. I. SQ109 targets MmpL3, a membrane transporter of trehalosemonomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2012, 56, 1797-1809
9. Makarov, V.; Manina, G.; Mikusová, K.; Möllmann, U.; Ryabova, O.; Saint-Joanis, B.; Dhar, N.; Pasca, M. R.; Buroni, S.; Lucarelli, A. P.; Milano, A.; De Rossi, E.; Belanova, M.; Bobovska, A.; Dianiskova, P.; Kordulakova, J.; Sala, C.; Fullam, E.; Schneider, P.; McKinney, J. D.; Brodin, P.; Christophe, T.; Waddell, S.; Butcher, P.; Albrethsen, J.; Rosenkrands, I.; Brosch, R.; Nandi, V.; Bharath, S.; Gaonkar, S.; Shandil, R. K.; Balasubramanian, V.; Balganesh, T.; Tyagi, S.; Grosset, J.; Riccardi, G.; Cole, S. T. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis Science 2009, 324, 801-804
10. Shirude, P. S.; Shandil, R.; Sadler, C.; Naik, M.; Hosagrahara, V.; Hameed, S.; Shinde, V.; Bathula, C.; Humnabadkar, V.; Kumar, N.; Reddy, J.; Panduga, V.; Sharma, S.; Ambady, A.; Hegde, N.; Whiteaker, J.; McLaughlin, B.; Gardner, H.; Madhavapeddi, P.; Ramachandran, V.; Kaur, P.; Narayan, A.; Guptha, S.; Awasthy, D.; Narayan, C.; Mahadevaswamy, J.; Vishwas, K. G.; Ahuja, V.; Srivastava, A.; Prabhakar, K. R.; Bharath, S.; Kale, R.; Ramaiah, M.; Roy Choudhury, N.; Sambandamurthy, V.; Solapure, S.; Iyer, P.; Narayanan, S.; Chatterji, M. Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo J. Med. Chem. 2013, 56, 9701-9708
11. Yosu, V.; Eneko, A.; Ana, A.; Jos̈e, L. P.; Maŕia, I. A.; Fernando, P. C. Regiochemistry of the microwave-assisted reaction between aromatic amines and a-bromoketones to yield substituted 1H-indolesi Org. Biomol. Chem. 2008, 6, 1763-1772
12. Siavosh, M.; Emerich, E.; Matthias, W.; Andreas, S.; Ute, M. Antibacterial activity of a novel series of 3-bromo-4-(1 H -3-indolyl)-2,5-dihydro-1 H -2,5-pyrroledione derivatives: An extended structure-activity relationship study Eur. J. Med. Chem. 2008, 43, 633-656
13. Amblard, F.; Zhang, H.; Zhou, L.; Shi, J.; Bobeck, D. R.; Nettles, J. H.; Chavre, S.; McBrayer, T. R.; Tharnish, P.; Whitaker, T.; Coats, S. J. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 2031-2034
14. Wayne, L. G.; Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence Infect. Immun. 1996, 64, 2062-2069